A future investigation is needed to clarify the relationship between FGF23, bone microarchitecture, BMD, and bone remodelling biomarkers, which are adjusted for potential confounders (e.g., gender, BMI, sex hormones, PTH, and serum mineral levels), to establish the clinical potential of FGF23 in CKD-MBD. Here, PTH is linked to chronic kidney disease.